Biocartis shareholders 'expected to receive nothing' in stock market exit

Mechelen-based biotech company Biocartis is to drastically restructure its debt and liquidate its listed holding company. Shareholders are "expected to receive nothing" in the wind-down, the company said.

Biocartis produces molecular tests that can detect various types of cancer. The company has been in poor financial health for some time.

On Tuesday, the company announced a major debt restructuring and recapitalisation. It will reduce its debt by 132 million euros and raise 40 million euros in additional capital.

Secured creditors will take ownership of Biocartis' operating subsidiaries as the listed holding company is liquidated.

Shareholders, on the other hand, will be left empty-handed. They "will receive no distribution from the security enforcement and are expected to receive nothing at the time of its wind-down", the company said.



Related news

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.


Belga News Agency delivers dependable, rapid and high-quality information 24 hours a day, 7 days a week, from Belgium and abroad to all Belgian media. The information covers all sectors, from politics, economics and finance to social affairs, sports and culture, not to mention entertainment and lifestyle.

Every day, our journalists and press photographers produce hundreds of photos and news stories, dozens of online information items, plus audio and video bulletins, all in both national languages. Since the end of March 2022 English has been added as a language.

For public institutions, businesses and various organisations that need reliable information, Belga News Agency also offers a comprehensive range of corporate services to meet all their communication needs.


Arduinkaai 29 1000 Brussels